Projets financés
– PGxMTB
AAP2025 transnational dans le cadre de l'EP PerMed
2025
Personalised oncology has seen the development of drugs tailored to genetic variants associated with cancer biology. However, the full potential of targeted therapy remains untapped due to the predominant focus on acquired, tumor-specific alterations. Optimised cancer care must therefore integrate p
